TNF-Alpha Inhibition for Treatment of Alzheimer's Disease

• Status: Completed
• Trial end date: 2006-04-01
• Target enrollment: 0
• Participant gender: All

Summary

It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tobinick, Edward Lewis, M.D.
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• NINCDS-ADRDA Criteria for Alzheimer's disease

• CT or MRI consistent with AD

Exclusion Criteria:

• active infection

• CHF

• demyelinating disease

• uncontrolled diabetes mellitus

• vascular dementia

• clinically significant neurologic disease other than AD

• Hachinski >4

• history of lymphoma

• TBC

• wbc<2500

• platelets<100,000

• HCT<30

• pregnancy

• premenopausal, fertile not on acceptable birth control

• change in neuroactive medication within 4 weeks of study initiation